I am a scientist working at the University of Sussex. My main research interest is the control of the eukaryotic cell cycle.
My lab investigates how cells switch between interphase and mitosis.
Research Interests
- ▸ G2/M switch and mitotic entry regulation
- ▸ Kinases and Phosphatases that coordinate mitotic entry and exit
- ▸ Cancer biology of G2/M regulation
Methodology
- ▸ Chemical Genetics and Gene Targeting
- ▸ High content and super resolution microscopy
- ▸ Image processing and analysis using Python
Career Timeline
| Period | Position | Institution |
|---|---|---|
| 2022 - Present | Professor in Genome Stability | University of Sussex, UK |
| 2016 - 2022 | Reader in Genome Stability | University of Sussex, UK |
| 2012 - 2018 | CRUK Senior Research Fellow | University of Sussex, UK |
| 2007 - 2012 | Wellcome Trust Career Development Fellow | University of Sussex, UK |
| 2002 - 2007 | Postdoctoral Researcher | Kyoto University, Japan (with S. Takeda) |
| 1998 - 2002 | PhD Student | ICRF Clare Hall, UK (with T. Hunt) |
| 1998 | Diplom Biochemistry | Freie Universitaet Berlin, Germany |
Publications
Recent Contributions
-
The balance between B55α and Greatwall expression levels predicts sensitivity to Greatwall inhibition in cancer cells
Nature Communications (2025)
-
Sumo-regulatory SENP2 controls the homeostatic squamous mitosis-differentiation checkpoint
Cell Death & Disease (2024)
-
Genetic instability from a single S phase after whole-genome duplication
Nature, 604(7904):146-151 (2022)
-
Prophase-Specific Perinuclear Actin Coordinates Centrosome Separation and Positioning
Cell Reports, 31: 107681 (2020)
-
Cyclin A triggers Mitosis either via the Greatwall kinase pathway or Cyclin B
EMBO Journal, 61: e104419 (2020)
-
Two Interlinked Bistable Switches Govern Mitotic Control in Mammalian Cells
Current Biology, 28(23): 3824–3832.e6 (2018)
-
DNA Replication Determines Timing of Mitosis by Restricting CDK1 and PLK1 Activation
Molecular Cell, 71:117–128.e3 (2018)
Current Funding
Exploiting a new cell cycle control pathway for cancer therapy
2022-2027
Validating a new combinatorial approach for Palbociclib to target triple-negative breast cancer
2022-2025